Back to discover
Disease

WHIM syndrome 1

Also known as WHIM Syndrome, WHIMS, WILM, Warts, hypogammaglobulinemia, infections, and myelokathexis+5 more

WHIM Syndrome, WHIMS, WILM, Warts, hypogammaglobulinemia, infections, and myelokathexis, Warts, hypogammaglobulinemia, infections, and myelokathexis syndrome, Warts-hypogammaglobulinemia-infections-myelokathexis syndrome, Warts-infections-leukopenia-myelokatexis syndrome, myelokathexis, isolated, WHIM syndrome.

1
Associated genes
1
Related proteins

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Low
Key developments
  • 1 regulatory approval from EMA on record.
Major developments
Important regulatory approvalHigh impact
Approval — Mavorixafor
Xolremdi is indicated in patients 12 years of age and older for the treatment of WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis) to increase the number of circulating mature neutrophils and lymphocytes.2026-04-27
Regulatory Updates1View
  • 2026-04-27Approval — MavorixaforXolremdi is indicated in patients 12 years of age and older for the treatment of WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis) to increase the number of circulating mature neutrophils and lymphocytes.
Activity timeline1
  • 2026-04-27RegulatoryApproval — MavorixaforXolremdi is indicated in patients 12 years of age and older for the treatment of WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis) to increase the number of circulating mature neutrophils and lymphocytes.

Therapeutic landscape

Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.

Approved & established therapies
Mavorixaforapproved

Approval — Xolremdi is indicated in patients 12 years of age and older for the treatment of WHIM syn… (2026)

Regulatory timeline

Drug regulatory events matched to this condition by indication — EMA.

First approvals
2026emaApproval — Mavorixafor· Xolremdi is indicated in patients 12 years of age and older for the treatment of WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis) to increase the number of circulating mature neutrophils and lymphocytes. source ↗

European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.

Associated genes

1 match

Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.

CXCR40.77

Disease biology

1 match

Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.

C-X-C chemokine receptor type 4via CXCR40.77

Reference

Authoritative identity, definition & identifiers.

Synonyms

WHIM Syndrome, WHIMS, WILM, Warts, hypogammaglobulinemia, infections, and myelokathexis, Warts, hypogammaglobulinemia, infections, and myelokathexis syndrome, Warts-hypogammaglobulinemia-infections-myelokathexis syndrome, Warts-infections-leukopenia-myelokatexis syndrome, myelokathexis, isolated, WHIM syndrome

References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.